PreveCeutical Medical Inc (TSE:PREV)
:PREV
Want to see TSE:PREV full AI Analyst Report?
PREV Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.06
Previous CloseN/A
Volume100.00K
Average Volume (3M)143.42K
Market Cap
C$8.97M
Enterprise ValueC$16.63M
Total Cash (Recent Filing)C$10.24K
Total Debt (Recent Filing)C$4.68M
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding598,186,950
10 Day Avg. Volume276,937
30 Day Avg. Volume143,419
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D And IP Focus With Partner CommercializationThe company’s explicit emphasis on developing intellectual property and pursuing commercialization via partners is a durable strategic choice. Partner-led commercialization can reduce capital intensity, accelerate market access, and let the firm concentrate on R&D and licensing rather than building full commercial infrastructure.
Pipeline Diversity In Drug Delivery And Cannabinoid TherapeuticsMaintaining programs across drug delivery platforms and cannabinoid-related therapeutics spreads technical and market risk. Structurally, these areas have growing scientific and regulatory interest, allowing multiple development or licensing avenues that can sustain the business over a multi-quarter horizon if programs progress.
Lean Operating FootprintA very small employee base implies low fixed overhead and a lean operating model. This durable operational posture can extend runway between financings, concentrate spend on core R&D tasks, and make it easier to scale via partnerships or contract resources as programs advance.
Bears Say
No Commercial RevenueThe absence of any reported revenue across several years signals the business has not yet validated a commercial product or sustainable cash inflow. Over the medium term this forces reliance on external funding or deals; without revenue, execution risk and funding uncertainty remain primary structural threats to viability.
Negative Equity And Rising DebtPersistently negative equity and increasing borrowings constrain financial flexibility and elevate refinancing and solvency risk. Structurally, this limits the company’s ability to fund development internally, increases likelihood of dilutive financings or restrictive covenants, and hampers long-term strategic optionality.
Accelerating Cash Burn And Weak Cash GenerationOperating cash flow and free cash flow are deeply negative and worsened in the latest year, indicating accelerating cash burn. This structural cash-generation shortfall makes the firm dependent on external financing or partner deals for continuity, increasing execution and dilution risk over the medium term.
PreveCeutical Medical News
PREV FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is C$8.97M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Aug 20, 2026 which is in 72 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
Currently, no data Available
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 598,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in TSE:PREV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―
Options Prices
Currently, No data available
---